Drug penetration in solid tumours

Nature Reviews Cancer

Volumn 6, Issue 8, 2006, Pages 583-592

  Minchinton, Andrew I ^a   Tannock, Ian F ^b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FOLIC ACID; GEFITINIB; GEMCITABINE; GLYCOPROTEIN P INHIBITOR; HOE 33342; IMATINIB; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; NITROIMIDAZOLE; OMEPRAZOLE; PACLITAXEL; PIMONIDAZOLE; PR 104; TIRAPAZAMINE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; HUMAN; ISOTOPE LABELING; MOLECULAR MECHANICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR SPHEROID;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 33746491709     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1893     Document Type: Review

References (145)

1. Tannock, I. F. & Hayashi, S. The proliferation of capillary endothelial cells. Cancer Res. 32, 77-82 (1972).
2. Denekamp, J. & Hobson, B. Endothelial-cell proliferation in experimental tumours. Br. J. Cancer 46, 711-20 (1982).
3. Thomlinson, R. H. & Gray, L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9, 539-549 (1955). This landmark article suggested that the hypoxic cells within human tumours were resistant to radiation therapy.
4. Less, J. L., Skalak, E. M., Sevick, E. M. & Jain, R. K. Micrvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res. 51, 265-273 (1991).
5. Brown, J. M. & Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416 (1998).
6. Intaglietta, M., Myers, R. R., Gross, J. F. & Reinhold, H. S. Dynamics of microvascular flow in implanted mouse mammary tumours. Bibl. Anat. 15 Pt 1, 273-276 (1977).
7. Chaplin, D. J., Olive, P. L. & Durand, R. E. Intermittent blood flow in a murine tumour: Radiobiological effects. Cancer Res. 47, 597-601 (1987). Describes intermittent blood flow in an experimental tumour and suggests a second mechanism by which tumour cells can become hypoxic.
8. Chaplin, D. J., Trotter, M. J., Durand, R. E., Olive, P. L. & Minchinton, A. I. Evidence for intermittent radiobiological hypoxia in experimental tumour systems. Biomed. Biochim. Acta 48, 255-259 (1989).
9. Dewhirst, M. W., Braun, R. D. & Lanzen, J. L. Temporal changes in PO2 of R3230AC tumors in Fischer-344 rats. Int J Radiat Oncol Biol Phys 42, 723-726 (1998)
10. Padera, T. P. et al. Pathology: cancer cells compress intratumour vessels. Nature 427, 695 (2004).
11. Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nature Rev. Cancer 4, 437-447 (2004).
12. Leu, A. J., Berk, D. A., Lymboussaki, A., Alitalo, K. & Jain, R. K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 60, 4324-4327 (2000).
13. Jain, R. K., Munn, L. L. & Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. Nature Rev. Cancer 2, 266-276 (2002).
14. Jain, R. K. Delivery of molecular and cellular medicine to solid yumors. Microcirculation 4, 3-21 (1997).
15. Milosevic, M. F. et al. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer 82, 2418-2426 (1998).
16. Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure - an obstacle in cancer therapy. Nature Rev. Cancer 4, 806-813 (2004). An excellent review of IFP in cancer.
17. Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J. & Jain, R. K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60, 2497-2503 (2000).
18. Davies Cde, L., Berk, D. A., Pluen, A. & Jain, R. K. Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br. J. Cancer 86, 1639-1644 (2002).
19. Brown, E. et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nature Med. 9, 796-800 (2003).
20. Jain, R. K. Barriers to drug delivery in solid tumours. Sci. Amer. 271, 59-65 (1994).
21. Tannock, I. F. & Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49, 4373-4384 (1989).
22. Raghunand, N., Gatenby, R. A. & Gillies, R. J. Microenvironmental and cellular consequences of altered blood flow in tumours. Br. J. Radiol. 76 Spec No. 1, S11-S22 (2003).
23. Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nature Rev. Cancer 4, 891-899 (2004).
24. Moulder, J. E. & Rockwell, S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev. 5, 313-341 (1987).
25. Harris, A. L. Hypoxia - a key regulatory factor in tumour growth. Nature Rev. Cancer 2, 38-47 (2002).
26. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nature Rev. Cancer 5, 275-284 (2005).
27. Tannock, I. F. The relation between cell proliferation and vascular system in a transplanted mouse mammary tumour. Br. J. Cancer 22, 258-273 (1968). A pivotal report on the gradient in cell proliferation kinetics as a function of distance from tumour vasculature.
28. Hirst, D. G. & Denekamp, J. Tumour cell proliferation in relation to the vasculature. Cell Tissue Kinet. 12, 31-42 (1979).
29. Tannock, I. Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep. 62, 1117-1133 (1978).
30. Brown, J. M. NCI's anticancer drug screening program may not be selecting for clinically active compounds. Oncol. Res. 9, 213-215 (1997).
31. van der Greef, J. & McBurney, R. N. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nature Rev. Drug Discov. 4, 961-967 (2005).
32. Allen, L., Kimura, K., MacKitchan, J. & Ritschel, W. A. Manual of symbols, equations and definitions in pharmacokinetics. J. Clin. Pharmacol. 22, 1S-23S (1982).
33. Rentsch, K. M. et al. Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer. Eur. J. Clin. Pharmacol. 54, 83-89 (1998).
34. Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363-1380 (2000).
35. Hobbs, S. K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607-4612 (1998).
36. Yuan, F. et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752-3756 (1995).
37. Jain, R. K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 47, 3039-3051 (1987).
38. Crank, J. The Mathematics of Diffusion (Clarendon Press, Oxford, 1975).
39. Coley, H. M., Amos, W. B., Twentyman, P. R. & Workman, P. Examination by laser scanning confocal fluorescence imaging microscopy of subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br. J. Cancer 67, 1316-1323 (1993).
40. Lee, C. M. & Tannock, I. F. Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration. Br. J. Cancer (2006).
41. Sutherland, R. M. & Durand, R. E. Radiation response of multicell spheroids - an in vitro tumour model. Curr. Top. Radiat. Res. Q. 11, 87-139 (1976).
42. Sutherland, R. M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240, 177-184 (1988).
43. Durand, R. E. Variable radiobiological responses of spheroids. Radiat. Res. 81, 85-99 (1980).
44. Sutherland, R. M., Eddy, H. A., Bareham, B., Reich, K. & Vanantwerp, D. Resistance to adriamycin in multicellular spheroids. Int. J. Radiat. Oncol. Biol. Phys. 5, 1225-1230 (1979).
45. Kerr, D. J. & Kaye, S. B. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother. Pharmacol. 19, 1-5 (1987).
46. Kerr, D. J., Wheldon, T. E., Hydns, S. & Kaye, S. B. Cytotoxic drug penetration studies in multicellular tumour spheroids. Xenobiotica 18, 641-648 (1988).
47. Durand, R. E. Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage? Cancer Chemother. Pharmacol. 26, 198-204 (1990).
48. West, G. W., Weichselbaum, R. & Little, J. B. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res. 40, 3665-3668 (1980).
49. Wibe, E. Resistance to vincristine of human cells grown as multicellular spheroids. Br. J. Cancer 42, 937-941 (1980).
50. Nederman, T., Carlsson, J. & Malmqvist, M. Penetration of substances into tumor tissue - a methodological study on cellular spheroids. In Vitro 17, 290-298 (1981).
51. Nederman, T. & Carlsson, J. Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother. Pharmacol. 13, 131-135 (1984).
52. Sutherland, R., Buchegger, F., Schreyer, M., Vacca, A. & Mach, J. P. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res. 47, 1627-1633 (1987).
53. Mairs, R. J., Angerson, W. J., Babich, J. W. & Murray, T. Differential penetration of targeting agents into multicellular spheroids derived from human neuroblastoma. Prog. Clin. Biol. Res. 366, 495-501 (1991).
54. Erlanson, M., Daniel-Szolgay, E. & Carlsson, J. Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids. Cancer Chemother. Pharmacol. 29, 343-353 (1992).
55. Erlichman, C. & Vidgen, D. Cytotoxicity of adriamycin in MGH-U1 cells grown as monolayer cultures, spheroids, and xenografts in immune-deprived mice. Cancer Res. 44, 5369-5375 (1984).
56. Durand, R. E. Use of Hoechst 33342 for cell selection from multicell systems. J. Histochem. Cytochem. 30, 117-122 (1982). Description of an important flow cytometry method whereby tumour cells can be sorted from tumours on the basis of their proximity to blood vessels.
57. Durand, R. E. Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment. J. Natl Cancer Inst. 77, 247-252 (1986).
58. Olive, P. L. & Durand, R. E. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev. 13, 121-138 (1994).
59. Oloumi, A., Lam, W., Banath, J. P. & Olive, P. L. Identification of genes differentially expressed in V79 cells grown as multicell spheroids. Int. J. Radiat. Biol. 78, 483-492 (2002).
60. Teicher, B. A. et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247, 1457-1461 (1990).
61. Kobayashi, H. et al. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc. Natl Acad. Sci. USA 90, 3294-3298 (1993).
62. Hicks, K. O. et al. An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br. J. Cancer 76, 894-903 (1997).
63. Minchinton, A. I., Wendt, K. R., Clow, K. A. & Fryer, K. H. Multilayers of cells growing on a permeable support: an in vitro tumour model. Acta Oncologica 36, 13-16 (1997).
64. Cowan, D. S. M., Hicks, K. O. & Wilson, W. R. Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br. J. Cancer 74, S28-S31 (1996).
65. Hicks, K. O., Fleming, Y., Siim, B. G., Koch, C. J. & Wilson, W. R. Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys. 42, 641-649 (1998).
66. Tannock, I. F., Lee, C. M., Tunggal, J. K., Cowan, D. S. & Egorin, M. J. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res. 8, 878-884. (2002).
67. Phillips, R. M., Loadman, P. M. & Cronin, B. P. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br. J. Cancer 77, 2112-2119 (1998).
68. Tunggal, J. K., Cowan, D. S., Shaikh, H. & Tannock, I. F. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin. Cancer Res. 5, 1583-1586 (1999).
69. Kyle, A. H., Huxham, L. A., Chiam, A. S., Sim, D. H. & Minchinton, A. I. Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture. Cancer Res. 64, 6304-6309 (2004).
70. Hicks, K. O., Pruijn, F. B., Baguley, B. C. & Wilson, W. R. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells. J. Pharmacol. Exp. Ther. 297, 1088-1098 (2001).
71. Hicks, K. O., Pruijn, F. B., Sturman, J. R., Denny, W. A. & Wilson, W. R. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res. 63, 5970-5977 (2003).
72. Kyle, A. & Minchinton, A. I. Measurement of delivery and metabolism of tirapazamine through tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol. 43, 213-220 (1999).
73. Wilson, W. R. & Hicks, K. O. Measurement of extravascular drug diffusion in multicellular layers. Br. J. Cancer 79, 1623-1626 (1999).
74. Grantab, R., Sivananthan, S. & Tannock, I. F. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res. 66, 1033-1039 (2006).
75. Goldacre, R. J. & Sylvén, B. A rapid method for studying tumour blood supply using systemic dyes. Nature 184, 63-64 (1959).
76. Goldacre, R. J. & Sylvén, B. On the access of bloodborne dyes to various tumour regions. Br. J. Cancer 16, 306-322 (1962). Excellent and comprehensive review of early studies (pre 1960) of tumour vasculature and their relevance to drug delivery.
77. Egorin, M. J., Hildebrand, R. C., Cimino, E. F. & Bachur, N. R. Cytofluorescence localisation of adriamycin and daunomycin. Cancer Res. 34, 2243-2245 (1974).
78. Ozols, R. F. et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 39, 3209-3214 (1979).
79. Henneberry, H. P. & Aherne, G. W. Visualisation of doxorubicin in human and animal tissues and in cell cultures by immunogold-silver staining. Br. J. Cancer 65, 82-86 (1992).
80. Henneberry, H. P., Aherene, G. W. & Marks, V. Immunocytochemical localisation of VP16-213 in normal and malignant tissues. Cancer Lett. 37, 225-233 (1987).
81. Jain, R. K., Weissbrod, J. M. & Wei, J. Mass transport in tumors: characterization and applications to chemotherapy. Adv. Cancer Res. 33, 251-310 (1980).
82. Simpson-Herren, L., Noker, P. E. & Wagoner, S. D. Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity. Cancer Chemother. Pharmacol. 22, 131-136 (1988).
83. Simpson-Herren, L. & Noker, P. E. Diversity of penetration of anti-cancer agents into solid tumours. Cell Prolif. 24, 355-365 (1991).
84. Chaplin, D. J., Durand, R. E. & Olive, P. L. Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br. J. Cancer 51, 569-572 (1985).
85. Gerlowski, L. E. & Jain, R. K. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31, 288-305 (1986).
86. Dewhirst, M. W. et al. Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber. Radiat. Res. 130, 171-182 (1992).
87. Leunig, M. et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res. 52, 6553-6560 (1992).
88. Wu, N. Z., Klitzman, B., Rosner, G., Needham, D. & Dewhirst, M. W. Measurement of material extravasation in microvascular networks using fluorescence video-microscopy. Microvosc. Res. 46, 231-253 (1993).
89. Helmlinger, G., Yuan, F., Dellian, M. & Jain, R. K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nature Med. 3, 177-182 (1997).
90. Dreher, M. R. et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl Cancer Inst. 98, 335-344 (2006).
91. Brown, E. B. et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nature Med. 7, 864-868 (2001).
92. Tong, R. T. et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736 (2004).
93. Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563 (2004).
94. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145-147 (2004).
95. Kuh, H. J., Jang, S. H., Wientjes, M. G., Weaver, J. R. & Au, J. L. Determinants of paclitaxel penetration and accumulation in human solid tumor. J. Pharmacol. Exp. Ther. 290, 871-880 (1999).
96. Jang, S. H., Wientjes, M. G., Lu, D. & Au, J. L. Drug delivery and transport to solid tumors. Pharm. Res. 20, 1337-1350 (2003).
97. Terheggen, P. M. et al. Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1- cyclobutanedicarboxylato) platinum(II) with DNA in rodent tissue sections. Cancer Res. 47, 6719-6725 (1987).
98. Meijer, C. et al. Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopy. Br. J. Cancer 76, 290-298 (1997).
99. Raleigh, J. A. et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 58, 3765-3768 (1998).
100. Huxham, L. A., Kyle, A. H., Baker, J. H. E., McNicol, K. L. & Minchinton, A. I. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiother. Oncol. 78, 138-145 (2006).
101. Lankelma, J. et al. Doxorubicin gradients in human breast cancer. Clin. Cancer Res. 5, 1703-1707 (1999).
102. Primeau, A. J., Rendon, A., Hedley, D., Lilge, L. & Tannock, I. F. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res. 11, 8782-8788 (2005).
103. Koch, C. J., Evans, S. M. & Lord, E. M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2, 2, 3, 3, 3-pentafluoropropyl) acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br. J. Cancer 72, 869-874 (1995).
104. Huxham, L. A., Kyle, A. H., Baker, J. H., Nykilchuk, L. K. & Minchinton, A. I. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res. 64, 6537-6541 (2004).
105. Wu, L. & Tannock, I. F. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. Clin. Cancer Res. 11, 8195-8200 (2005).
106. Kyle, A. H., Huxham, L. A., Baker, J. H., Burston, H. E. & Minchinton, A. I. Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent. Cancer Res. 63, 5707-5711 (2003).
107. Sherar, M. D. Imaging in Oncology. in The Basic Science of oncology (eds Tannock, I. F., Hill, R. P., Bristow, R. G. & Harrington, L.) 249-260 (McGrow-Hill, New York, USA, 2005).
108. Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. Nature Rev. Cancer 2, 683-693 (2002).
109. Durand, R. E. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res. 41, 3495-3498 (1981).
110. Kim, J. J. & Tannock, I. F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nature Rev. Cancer 5, 516-525 (2005).
111. Brown, J. M. SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 67, 1163-1170 (1993).
112. Rischin, D. et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19, 535-542 (2001).
113. Rischin, D. et al. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98. 02). J. Clin. Oncol. 23, 79-87 (2005).
114. Hicks, K. O., Siim, B. G., Pruijn, F. B. & Wilson, W. R. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors. Radiat. Res. 161, 656-666 (2004).
115. Baxter, L. T., Zhu, H., Mackensen, D. G., Butler, W. F. & Jain, R. K. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 55, 4611-4622 (1995).
116. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
117. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
118. Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
119. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279-280. (2002).
120. Pruijn, F. B. et al. Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. J. Med. Chem. 48, 1079-1087 (2005).
121. Siim, B. G. et al. Hypoxia-selective 3-alkyl-1, 2, 4-benzotriazine 1, 4-dioxide bioreductive drugs: Analogues of tirapazamine with improved in vivo activity. Clin. Cancer Res. 11, 8973s (2005).
122. Hicks, K. O. et al. Penetration of three dimensional tissue culture predicts in vivo activity of hypoxia-targeted anticancer drugs. J. Natl Cancer. Inst (in the press)
123. Minchinton, A. I., Durand, R. E. & Chaplin, D. J. Intermittent blood flow in the KHT sarcoma- flow cytometry studies using Hoechst 33342. Br. J. Cancer 62, 195-200 (1990).
124. Kotelnikov, V. M. et al. In vivo labelling with halogenated pyrimidines of squamous cell carcinomas and adjacent non-involved mucosa of head and neck region. Cell Prolif. 28, 497-509 (1995).
125. Boucher, Y. & Jain, R. K. Microvascular pressure is the principle driving force for interstitial hypertension in solid tumours: Implications for vascular collapse. Cancer Res. 52, 5110-5114 (1992).
126. Jain, R. K. Molecular regulation of vessel maturation. Nature Med. 9, 685-693 (2003). A review of vascular structure and architecture within tumours, and a discussion of vessel normalization phenomenon.
127. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
128. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 7, 987-989 (2001).
129. Franco, M. et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 66, 3639-3648 (2006).
130. Riesterer, O. et al. Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin. Cancer Res. 12, 3518-3524 (2006).
131. Cowan, D. S. & Tannock, I. F. Factors that influence the penetration of methotrexate through solid tissue. Int. J. Cancer 91, 120-125 (2001).
132. Tunggal, J. K., Melo, T., Ballinger, J. R. & Tannock, I. F. The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int. J. Cancer 86, 101-107 (2000).
133. Milroy, R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. Br. J. Cancer 68, 813-818 (1993).
134. Wishart, G. C. et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J. Clin. Oncol. 12, 1771-1777 (1994).
135. Kerbel, R. S., St Croix, B., Florenes, V. A. & Rak, J. Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum. Cell 9, 257-264 (1996).
136. St Croix, B., Man, S. & Kerbel, R. S. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett. 131, 35-44 (1998).
137. Jang, S. H., Wientjes, M. G. & Au, J. L. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J. Pharmacol. Exp. Ther. 296, 1035-1042 (2001).
138. Griffon-Etienne, G., Boucher, Y., Brekken, C., Suit, H. D. & Jain, R. K. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 59, 3776-3782 (1999).
139. McKee, T. D. et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66, 2509-2513 (2006).
140. Mayer, L. D., Bally, M. B. & Cullis, P. R. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta 857, 123-126 (1986).
141. Millot, C., Millot, J. M., Morjani, H., Desplaces, A. & Manfait, M. Characterization of acidic vesicles in multidrug-resistant and sensitive cancer cells by acridine orange staining and confocal microspectrofluorometry. J. Histochem. Cytochem. 45, 1255-1264 (1997).
142. Poole, B. & Ohkuma, S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J. Cell. Biol. 90, 665-669 (1981).
143. Mattsson, J. P., Vaananen, K., Wallmark, B. & Lorentzon, P. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim. Biophys. Acta 1065, 261-268 (1991).
144. Vail, D. M. et al. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin. Oncol. 31, 16-35 (2004).
145. Nyman, D. W. et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 23, 7785-7793 (2005).